GlassScriptPhysician profile
Gayl S Reader
NPI 1467401729
$26,944.07
in general payments reported to CMS, 2019-2025
30 companies · $978 in 2025
The $978 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,317 · 2021: $6,872 · 2022: $4,211 · 2023: $1,715 · 2024: $1,516 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,883.57 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,925.94 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $957.82 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $799.71 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.39 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $506.75 | 2019-2024 | Farxiga, Brilinta |
| Pfizer INC. | $472.89 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $312.55 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $227.60 | 2020-2021 | |
| Esperion Therapeutics, INC. | $191.15 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $147.99 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $120.53 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $117.28 | 2024-2025 | |
| Scpharmaceuticals INC. | $98.06 | 2023-2024 | |
| Abiomed | $89.84 | 2020-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $53.28 | 2019 | |
| Novo Nordisk INC | $44.71 | 2021 | |
| Boston Scientific Corporation | $41.50 | 2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| Amryt Pharma Holdings LTD | $38.86 | 2021 | |
| Lundbeck LLC | $34.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.00 | 2019 | |
| Terumo Medical Corporation | $19.28 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.80 | 2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $17.03 | 2025 | Onpattro |
| Abbott Laboratories | $16.22 | 2021 | |
| Chiesi USA, INC. | $15.21 | 2022 | |
| Cardiovascular Systems INC. | $15.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.01 | 2020 | |
| Aegerion Pharmaceuticals, INC. | $11.90 | 2019 | |
| Biosense Webster, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gayl Reader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.